Nuclear factor kB (NF-kB) is a transcription factor that controls the expression of many cellular and viral genes. The p65 (RelA) subunit plays a critical role as a transcriptional activator and recent observations have highlighted its role in the control of apoptosis. Here we report that 53BP2, a protein previously identi®ed by interaction with wild type p53 and Bcl-2, also binds to p65 in a yeast two-hybrid system. This speci®c interaction was con®rmed by pull-down assay in vitro and by a mammalian two-hybrid assay in vivo. We observed that full-length 53BP2 fused to GFP had a punctate distribution in cytoplasm, predominantly in perinuclear region whereas the N-terminal 53BP2 localized in cytoplasm and C-terminal 53BP2 localized in the nucleus. Furthermore, we found that overexpression of GFP-53BP2 induced apoptosis in transiently transfected cells. Neither the N-terminal nor the Cterminal of 53BP2 fused to GFP induced cell death. Interestingly, co-transfection with a p65 expression plasmid signi®cantly inhibited 53BP2-induced cell death. The previous ®ndings that 53BP2 bound to p53 and Bcl-2 together with our present observations suggest that 53BP2 may play a central role in the regulation of apoptosis and cell growth.
Introduction
53BP2 has been initially identi®ed by its ability to bind the core domain of p53 (Iwabuchi et al., 1994) . p53 protein has been implicated in an array of cellular functions including regulation of cell cycle, apoptosis, and gene expression (Hollstein et al., 1991; Prives and Manfridi, 1993) . Recent crystallographic analysis has provided a structural basis for p53-53BP2 interaction and demonstrated that the 53BP2 binding site on the p53 core domain consists of evolutionarily conserved regions that are frequently mutated in cancer and that it overlaps the site of DNA binding (Gorina and Pavletich, 1996) . The binding of 53BP2 to wild type p53 but not some mutant forms of p53 suggested that 53BP2 might be involved in some of the biological functions of p53 (Gorina and Pavletich, 1996; Thukral et al., 1994) . It has also been demonstrated that 53BP2 interacts with an apoptotic inhibitor Bcl-2 (Naumovski and Cleary, 1996) , and protein phosphatase 1 (PP1) (Helps et al., 1995) through the ankyrin repeats and the Src-homology-3 (SH3) domain in its C-terminus. The ankyrin repeats, the SH3 domain, and the central proline-rich region (a potential SH3 ligand motif) of 53BP2 appear to mediate protein ± protein interaction with speci®c proteins (Sparks et al., 1996; Thukral et al., 1994) . Since Bcl-2 prevented the binding of p53 to 53BP2 and even displaced p53 when it was bound to 53BP2 (Naumovski and Cleary, 1996) , this biochemical feature of Bcl-2 might be responsible for its ability to aect the p53-induced apoptosis. However, it is still an open question whether 53BP2 is involved in apoptosis probably due to its extremely low stability as a protein molecule in the cell (Gorina and Pavletich, 1996; Naumovski and Cleary, 1996) .
On the other hand, nuclear factor kappa B (NF-kB) encompasses a family of inducible transcriptional factors and is a critical regulator of the cellular responses to various environmental challenges including infectious agents, oxidative stress and chemical agents (for reviews, see Baeuerle and Baichwal, 1997; Hardin et al., 1992; Okamoto et al., 1997) . The NF-kB/Rel family is composed of p50, p65 (RelA), p52, RelB and c-Rel. The NF-kB is a heterodimer composed of p50 and p65. The p65 subunit is known to be repsonsible for transcriptional activation (Nolan et al., 1991) . NF-kB is retained in the cytoplasm by the inhibitory IkB proteins in an inactive form. The factor becomes readily activated when cells are stimulated with various agents such as in¯ammatory cytokines. In addition to its role in transcriptional activation, recent observations have highlighted its role in blocking the apoptosis pathway (Beg and Baltimore, 1996; Wang et al., 1996; Wu et al., 1996) .
Here, we demonstrate an evidence of molecular interaction between p65 and 53BP2 that has been obtained during our attempts to identify the interacting proteins with p65 by yeast two-hybrid screen. Either the ankyrin repeats or the SH3 domain of 53BP2 can bind to p65 in vitro. We also show that 53BP2 can induce cell death, which is inhibited by p65 overexpression.
Results

Isolation of 53BP2 cDNA clones as a p65-binding protein
In order to search for proteins interacting with NF-kB p65 subunit, human p65 cDNA fragment encompass-ing amino acid residues 176 ± 405 and excluding the Cterminal trans-activation domain was fused to the Gal4 DNA-binding domain in pAS2-1 vector and was used as a bait in two-hybrid screen with human placenta and brain cDNA libraries. We plated the 1.56610 6 yeast transformants in the absence of tryptophan, leucine, histidine and in the presence of 25 mM 3-AT, and the transformants were screened for the expression of Gal1-lacZ by b-galactosidase assay. Each plasmid puri®ed from the b-galactosidase positive clone was cotransfected with the bait plasmid into yeast strain Y187 and con®rmed the speci®c interaction by b-galactosidase assay. A total of 63 positive clones were thus identi®ed and further characterized by DNA sequencing.
Nucleotide sequencing of the isolated clones revealed that they contained genes encoding IkB-a/ MAD-3 (47 clones), IkB-b/Trip9 (4 clones), p105/NFkB1 (3 clones), p65/RelA (2 clones), c-Rel (1 clone), an unidenti®ed gene (4 clones) and 53BP2 (2 clones). Among these genes, we were interested in 53BP2 since it was initially identi®ed as a protein interacting with wild type p53 not with mutant forms (Iwabuchi et al., 1994) and was likely to be involved in the biological actions of p53 such as apoptosis (Gorina and Pavletich, 1996) . Two 53BP2 clones, independently isolated from brain and placenta (encompassing amino acid residues 227 ± 1005 and 477 ± 1005, respectively), contained the C-terminal region including ankyrin repeats and SH3 domain. These regions of 53BP2 were previously shown to be necessary for binding to p53 (Iwabuchi et al., 1994) , Bcl-2 (Naumovski and Cleary, 1996) and PP1 (Helps et al., 1995) .
Identi®cation of the regions of 53BP2 responsible for p65 binding
To con®rm the interaction between p65 and 53BP2 in vitro and to determine the regions necessary for binding to p65, three constructs were made in order to express various 53BP2 domains that were fused to the C-terminus of GST protein (Figure 1a ). These fusion proteins were expressed in E. coli BL21 and anity-puri®ed by glutathione-sepharose beads (Figure 1b) .
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S-methionine-labeled p65 was synthesized by in vitro transcription and translation. The puri®ed GST-fusion proteins bound to glutathionesepharose beads were incubated with the same amount of the labeled p65. The bound proteins were analysed by SDS ± PAGE. As shown in Figure  1c , p65 interacted strongly with the ankyrin repeats and the SH3 domain of 53BP2. Binding between p65 and 53BP2 was considered speci®c because no interaction of p65 was observed with either GST alone or with the proline-rich region of 53BP2 (Figure 1c ). Interaction of 53BP2 with p65 in yeast Since 53BP2 was isolated initially as a p53 binding protein in a yeast two-hybrid screen (Iwabuchi et al., 1994) , we used yeast two-hybrid assay to test the interaction of 53BP2 with p65 or p53. The interaction between p65 (176 ± 405) and p65 (176 ± 405) and that between p53 and T-antigen, as positive controls, were evident both for the colony growth on a 25 mM 3-AT plate and for the b-galactosidase assay. Interestingly, 53BP2 (477 ± 1005) interacted more strongly with p65 (176 ± 405) than with p53, as evidenced by the fact that p65 (176 ± 405)/53BP2 (477 ± 1005) colonies grew more quickly on a 3-AT plate and showed stronger bgalactosidase activity than p53/53BP2 (477 ± 1005) colonies. There was no detectable interaction between p53 and p65 (176 ± 405).
53BP2 interacted with p65 in vivo
To demonstrate the interaction between p65 and 53BP2 in vivo, we used a mammalian two-hybrid system in 293 and COS-1 cells. A luciferase reporter construct containing the Gal4 response element within the promoter region was co-transfected as an indicator for the interaction. As shown in Figure 3a , cotransfection with pM-53BP2 (full) and pVP16-p65 (full) activated transcription from the reporter gene about 14-fold. In control experiments, co-transfection of pM and pVP16-p65 (full) had a base level increment of about 5-fold and co-transfection of pM-53BP2 (full) and pVP16 did not activate the reporter gene.
The similar experiments were carried out to determine which part of p65 is responsible for binding to 53BP2. As shown in Figure 3b , co- Figure 2 53BP2 interacted with p65 (176 ± 405) stronger than with p53 in yeast two-hybrid system. Yeast Y190 was transformed with the indicated combinations of plasmids containing either Gal4 activation domain (AD) or Gal4 binding domain (BD). Filter assay was used to detect b-galactosidase activity. The growth on selective medium containing 25 mM 3-AT (3-AT plate) and the bgalactosidase activity are scored as a range from`7' (no growth on 3-AT plate and no b-galactosidase activity) to`++++' (activity generated by the interaction of p53 with SV40 T-antigen). The results with three independent clones are shown transfection with pM-53BP2 (477 ± 1005) and pVP16-p65 (176 ± 405) activated transcription (49-fold) from the reporter gene whereas plasmids containing either the N-terminus or C-terminus of p65, when cotransfected with pM-53BP2 (477 ± 1005), did not activate expression of the reporter gene. The interaction between pM-53BP2 (full) and pVP16-p65 (full) was lower than that between pM-53BP2 (477 ± 1005) and pVP16-p65 (176 ± 405) (compare Figure 3a with b), which might be due to the dierent intracellular localization of these proteins. These results indicated that 53BP2 interacted with the central region of p65 (176 ± 405) containing the dimerization domain, nuclear localization signal and the proline-rich motif, which was consistent with our results using the yeast two-hybrid system.
Tissue distribution of 53BP2 gene expression
We examined mRNA expression of 53BP2 and p65 in human tissues using Northern blot hybridization. As shown in Figure 4 , 53BP2 probe detected a transcript of approximately 4.4 kb. 53BP2 mRNA is ubiquitously expressed with large amounts in human heart, testis and peripheral blood leukocytes. However, it was markedly reduced in liver. An additional band of approximately 3.5 kb was observed only in brain. p65 mRNA was detected in all tissues examined. Since the endogenous 53BP2 protein could not be detected in various cell lines (Naumovski and Cleary, 1996 and our observation), we created plasmids expressing GFP fused with various portions of 53BP2 and determined the subcellular distribution of 53BP2. Fusion constructs containing GFP have been successfully used to study the subcellular localization of other proteins (Hollstein et al., 1991 and LippincottSchwartz, 1998 for review). In the transfected HeLa cells, GFP alone depicted a diuse distribution as previously reported (Figure 5b ) (Pines, 1995) . However, the full-length 53BP2 fused to GFP (pEGFP-53BP2 (full)) was located in the cytoplasm (Figure 5c ). A punctate vesicular pattern was noted, localized predominantly in the perinuclear region of the transfected cells. The same pattern of 53BP2 was observed by others (Naumovski and Cleary, 1996) , indicating that the GFP tag did not aect localization of 53BP2. The truncated 53BP2 without the ankyrin repeats and SH3 domain was localized in the cytoplasm, mostly in the perinuclear region without exhibiting a punctate pattern (Figure 5d ). Interestingly, the truncated 53BP2 with the ankyrin repeats and SH3 domain located predominantly in the nucleus (Figure 5e ). The similar distribution pattern was also observed in the transfected COS-1 cells (data not shown). We then examined whether 53BP2 was colocalized with the endogenous p65 in the transfected cells. HeLa cells were transfected with pEGFP-53BP2 (full) expressing GFP-53BP2 fusion protein and were subsequently stained with p65 antibody. As shown in Figure 5f and g, transfection with pEGFP-53BP2 (full) did not change the distribution of p65. GFP-53BP2 as well as endogenous p65 were located in the cytoplasm. The colocalization of GFP-53BP2 and p65 was shown by the overlay as yellow in Figure 5h .
53BP2 induced cell death in the transfected cells
When we transfected pEGFP-53BP2 (full) plasmid into HeLa and COS-1 cells, we observed that a signi®cant number of cells exhibited features characteristic for apoptosis such as rounded cell morphology with shrinking cytoplasm, blebbing and fragmented nuclei and condensed chromatin (Bellamy et al., 1995; Hardin et al., 1992) (Figure 6 ). These cells were also stained positively with Annexin V-PE, another characteristic feature of apoptosis (Martin et al., 1995) (Figure 6d and e). Similarly, these cells transfected with pEGFP-53BP2 were stained positively by TUNEL analysis (Graeber et al., 1996) (data not shown). In contrast, the cells expressing GFP or GFP fusion proteins with truncated 53BP2 mutants remained viable and did not show such characteristics (data not shown). The 
p65 protected 53BP2-transfected cells from cell death
We then investigated whether p65 could protect the cell death induced by 53BP2. In Figure 7 , HeLa cells were transfected with pEGFP or pEGFP-53BP2 (full) together with either the p65-expressing plasmid (CMV-p65) or its control vector. A signi®cant number of cells co-transfected with pEGFP-53BP2 and a control CMV vector exhibited apoptosis (Figure 7a and b) whereas most of the cells co-transfected wtih pEGFP-53BP2 and CMV-p65 exhibited normal cell morphology (Figure 7c and d) . As summarized in Figure 7e , cell death induced by GFP-53BP2 was 35.8+3.9% whereas co-transfection with the p65-expressing plasmid reduced the cell death rate to 9.8+1.5%, close to the control level of 11.5+3.0%.
To con®rm that the cell death induced by pEGFP-53BP2 was not caused by fusion with GFP protein, HeLa cells were co-transfected with pEGFP plasmid as a marker and pEBVHis-53BP2 in combination with CMV-p65 or control vector (Figure 7f ). Although the cell death induced by 53BP2 was not as ecient as that induced by GFP-53BP2, a signi®cant number of cells committed cell death as compared with the control (20.4+8.1% vs 10.8+6.9%, P50.05). Again, overexpression of p65 protected the 53BP2-transfected cells from cell death (the cell death rate was reduced to 8.1+1.1%).
To address the question whether p65 could protect the cells by decreasing the protein level of 53BP2, we carried out Western blot to determine the GFP-53BP2 protein level in the transfected cells. First, HeLa cells were transfected with a plasmid expressing GFP-53BP2 or GFP. As shown in Figure 8a , the protein level of GFP-53BP2 (lane 3) was dramatically reduced as compared with that of GFP (lane 2), which again supported an earlier notion that 53BP2 might be unstable in the cells (Naumovski and Cleary, 1996) . We then examined the eect of p65 overexpression on the amount of GFP-53BP2. In Figure 8b , p65 overexpression did not cause reduction of the GFP-53BP2 protein level at all (compare lanes 4 and 5). These observations clearly indicated that the eect of p65 overexpression in protecting the 53BP2-induced apoptosis was not through reducing the 53BP2 protein level in the transfected cells.
Discussion
Interaction between 53BP2 and other proteins such as p53, Bcl-2, PP1 have been previously reported and these interactions have been demonstrated through ankyrin repeats and SH3 domain of 53BP2 (Helps et al., 1995; Iwabuchi et al., 1994 ; Naumovski and Cleary, 1996) . Ankyrin repeats and SH3 domains are found in many proteins involved in signal transduction and are considered to mediate protein ± protein interaction (Bar-Sagi et al., 1993; Michaely and Bennett, 1993; Sparks et al., 1996; Yamabhai and Kay, 1997) . Although p65 was shown to interact with 53BP2 in mammalian cells (Figure 3) , we could not detect physical association of 53BP2 with NF-kB p65 by immunoprecipitation. In the reports by others no evidence was demonstrated to show the direct interaction of 53BP2 with p53, Bcl-2 and PP1 in mammalian cells (Helps et al., 1995; Iwabuchi et al., 1994; Naumovski and Cleary, 1996) . This is probably due to the low protein level or low stability of 53BP2 protein as we demonstrated in Figure 8a . By inspection of the amino acid sequence of 53BP2 , we found three distinct regions (547 ± 565, 675 ± 734 and 734 ± 767 amino acid residues) containing potential protein-destabilizing sequences with high PEST scores. Both 53BP2 and p65 genes are ubiquitously expressed in most of the tissues examined (Figure 4) , suggesting a physiological relevance of the interaction between 53BP2 and p65.
Since the endogenous 53BP2 was undetectable, we expressed GFP-53BP2 fusion protein to observe the subcellular distribution of 53BP2. We demonstrated that GFP-53BP2 displayed a punctate pattern of distribution, primarily in the cytoplasmic area near the nucleus in healthy cells. Interestingly, the similar distribution pattern was observed with Bcl-2 which was found associated with mitochondria (Wolter et al., 1997) . The results in Figure 5 indicated that the Nterminus of 53BP2 might sequestrate 53BP2 in cytoplasm while the C-terminus of 53BP2 might be required to be localized in the nucleus. These observations were consistent with a recent study that the ankyrin repeats of diverse proteins, such as IkBa and 53BP2, contained a functional nuclear import signal (Sachdev et al., 1998) . Although 53BP2 contains four ankyrin repeats and an SH3 domain that are characteristic of IkBs, we could not detect signi®cant eect of 53BP2 on NF-kB-dependent gene expression (data not shown).
We found that a signi®cant number of cells expressing full-length 53BP2 fused to GFP exhibited typical features of apoptosis and induced cell death ( Figure 6 ) whereas deleted 53BP2 mutant proteins failed to do so. These results indicated that neither the C-terminal region nor the N-terminal region were sucient to induce cell death. Experiments with these truncated 53BP2 proteins also suggested that both regions were necessary for proper intracellular localization. Naumovski et al. reported that 53BP2 did not induce apoptosis in transiently transfected NIH3T3 cells but impeded cell cycle progression at G2/M in the transfected 293 cells (Naumovski and Cleary, 1996) . The dierent inspection may be due to the dierence of the cells used or due to the stability of 53BP2 protein expressed. Therefore, 53BP2-mediated apoptosis may be dependent on cell types as well as protein stability. Our inability to establish a stable cell line expressing inducible 53BP2 using a teto system may be explained by this apoptosisinducing eect of 53BP2, even though there was only a trace amount of leaky expression of 53BP2 in this system (data not shown).
Currently we do not know whether 53BP2 alone can induce apoptosis or through binding with other proteins to cause cell death since amino acid sequence inspection of 53BP2 did not reveal any similarity with other known proapoptotic protein domains including death domain, BH3, and caspase domain. One of the possibilities is that 53BP2 may induce apoptosis through its interaction with p53 or Bcl-2 considering the facts that Bcl-2 prevented p53 from binding to 53BP2 (Naumovski and Cleary, 1996) and inhibited the p53-induced apoptosis Strasser et al., 1994) . In supporting our observation that 53BP2 induced cell death, it was recently reported that overexpression of 53BP2 could stimulate the p53-mediated transcriptional activation and could enhance the trans-activation of p21 gene (Iwabuchi et al., 1998) . It is possible, yet not proven, that the 53BP2-induced cell death may through p53-dependent pathway.
Interestingly, overexpression of p65 prevented the cell death induced by 53BP2 (Figure 7) . Several groups reported that activation of NF-kB prevented the cell death induced by TNFa, irradiation or genotoxic agents (Beg and Baltimore, 1996; Wang et al., 1996) . It was then suggested that this anti-apoptotic action of NF-kB might be mediated by inducing unknown genes responsible for prevention of cell death (Beg and Baltimore, 1996; Wang et al., 1996) . However, it is also noted that some genes that are induced by NF-kB, such as p53, Fas ligand and c-Myc, have been implicated in apoptosis (Klefstrom et al., 1997; Siebenlist et al., 1995) . Therefore, anti-apoptotic actions of NF-kB may not necessarily require its transcriptional activity. Although the mechanism of anti-apoptotic action of NF-kB is yet to be clari®ed, one of the possibilities may be through direct protein ± protein interaction.
The observations that 53BP2 bound p65 as well as p53 and Bcl-2 indicate that pro-apoptotic or antiapoptotic actions of these proteins may be through its interaction with 53BP2. In addition, there are a number of reports demonstrating the functional interrelationships among NF-kB, p53 and Bcl-2, such as activation of p53 by NF-kB (Wu and Lozano, 1994) , down-regulation of NF-kB by Bcl-2 (Grimm et al., 1996) and down-regulation of Bcl-2 by p53 (Selvakumaran et al., 1994) . Since p53, Bcl-2 and p65 are important regulatory factors involved in stress response, cell cycle regulation, cell growth, and apoptosis (Gottlieb and Oren, 1996; Siebenlist et al., 1995) , functional interactions among these proteins may determine the direction of cellular responses, which could be controlled by selective molecular interactions involving 53BP2 as a central regulator.
Materials and methods
Plasmids
Plasmids were constructed by standard methods (Sambrook et al., 1989) . The human p65 (amino acids 176 ± 405) cDNA fragment used in this two-hybrid screen was cloned into pAS2-1 (Clontech, Palo Alto, CA, USA) by PCR amplification of p65 cDNA. The resulting plasmid was named pAS2-1-p65 (176 ± 405). CMV-p65 plasmid was obtained from Dr Y Itoh and was derived from human RelA cDNA (Ruben et al., 1991) . Control plasmids, p53 in pAS2-1 and SV40 large T-antigen in pACT2, used in yeast two-hybrid were obtained from Clontech.
Full-length 53BP2 cDNA was cloned from human lymph node cDNA library (Clontech) as described previously . pGEX-5X-2 vector (Pharmacia Biotech) was used for expression of various 53BP2 proteins in E. coli. DNA fragments containing the proline-rich, the ankyrin repeats and the SH3 domain of the 53BP2 coding sequence (amino acid results 570 ± 778, 771 ± 992 and 914 ± 1005, respectively) were ampli®ed by PCR with the relevant oligonucleotide primers and cloned into pGEX-5X-2 vector.
The full-length 53BP2 was cloned into plasmid pEGFP-C1 (Clontech), yielding pEGFP-53BP2. pEGFP-53BP2 (1 ± 758) was generated from pEGFP-53BP2 by cutting with BamHI and ApaI, blunt ended with Klenow enzyme and ligated into pEGFP-C1. The pEGFP-53BP2 (759 ± 1005) was generated by amplifying the corresponding 53BP2 fragment by PCR using the oligonucleotides F759 (5'-CGAAAGAATTCCG-GAGAAGACTCGGTGA-3') and 53BP2R3 (5'-GGACTC-GAGAGGCCAAGCTCCTTGTC-3') and inserted into pEGFP-C1 vector. pEBVHis-53BP2 was generated for expression in the cultured cell by inserting the full-length 53BP2 fragment into pEBVHisB vector as described previously .
BamHI ± XhoI fragment obtained by digestion of the pACT2-53BP2 plasmid, encoding the shorter 53BP2 insert from the library search, was inserted into pM vector (Clontech), yielding pM-53BP2 (477 ± 1005). pM-53BP2 (full) was constructed by inserting the full-length 53BP2 cDNA into pM vector. Full-length p65 cDNA and the partial p65 cDNA fragments containing the amino acid residues corresponding 1 ± 181 and 399 ± 551 were ampli®ed by PCR using the relevant oligonucleotide primers and inserted into pVP16 vector, giving plasmids pVP16-p65 (full), pVP16-p65 (1 ± 181) and pVP16-p65 (399 ± 551), respectively. pVP16-p65 (176 ± 405) was generated from the pAS2-1-p65 (176 ± 405) and inserted into pVP16 vector (Clontech).
All the PCR used Expand high ®delity system (Boehringer Mannheim, Mannheim, Germany). All the constructs were con®rmed by dideoxynucleotide sequencing using ABI PRISM dye terminator cycle sequencing ready reaction kit (Perkin Elmer) on Applied Biosystems 310 automated DNA sequencer (Perkin Elmer).
Cell culture
COS-1, HeLa, and 293 cells were grown at 378C in Dulbecco's modi®ed Eagle's medium (DMEM) with 10% heat-inactivated fetal bovine serum, 1 mM glutamate, 100 U/ ml penicillin, and 100 mg/ml streptomycin.
Yeast two-hybrid screen
Plasmid pAS2-1-p65 (176 ± 405) was used as a bait. Y190 yeast strain was used for the library search (Fields and Song, 1989) . The Gal4 activation-domain cDNA libraries of human placenta and brain were obtained from Clontech and screened following the supplier's protocol. The transformants were plated on selective medium lacking tryptophan, leucine, and histidine and containing 25 mM 3-aminotriazole (3-AT) (Sigma). They were incubated at 308C for 5 ± 7 days. His+ colonies were analysed for b-galactosidase activity measured with 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (x-Gal) as substrate. Library-derived plasmids were rescued from these positive clones and transformed into E. coli HB101. Subsequent two-hybrid assays were carried out by introducing the plasmids into yeast strain Y187 and detected the expression of b-galactosidase to con®rm the speci®c interaction. Plasmids containing the cDNA clones that speci®cally interacted with p65 (176 ± 405) were identi®ed by restriction mapping, PCR using gene speci®c primers, and DNA sequencing of both strands. Sequence Network BLAST searches were conducted by using the National Center for Biotechnology Information (NCBI) on-line service.
Preparation of recombinant proteins and in vitro binding assays pGEX-5X-2 plasmids encoding GST-fusion proteins were transformed in E. coli strain BL21 (DE3) pLysS following induction with 0.1 mM IPTG (isopropyl-1-thio-b-D-galactopyranoside) at 288C overnight. Recombinant GST-fusion proteins were puri®ed with glutathione-sepharose beads (Pharmacia Biotech) according to the supplier's protocol. The purity and quantity of bound GST fusion proteins were examined by 5 ± 20% SDS ± PAGE. The 35 S-methioninelabeled p65 was synthesized using the TNT T7/SP6 wheat germ extract coupled system (Promega) according to the manufacturer's protocol. For in vitro protein interaction studies, an equal amount of the 35 S-methionine-labeled p65 was incubated with 5 mg of the puri®ed GST-53BP2 fusion protein or GST (as a negative control) bound to glutathionesepharose beads at 258C for 1 h. Bound proteins were eluted with an equal volume of SDS loading buer, boiled for 3 min, resolved by 5 ± 20% SDS ± PAGE, and visualized by autoradiography.
Mammalian two-hybrid assay COS-1 or 293 cells were transfected with a pVP16 plasmid (0.6 mg), expressing either full-length or truncated p65 fused to the VP16 activation domain, a pM plasmid (0.6 mg), expressing either full-length or truncated 53BP2 fused to the DNA-binding domain of Gal4, and pFR-luc luciferase reporter plasmid (0.25 mg) (Stratagene) using SuperFect transfection reagent (Qiagen). These plasmid constructions are described above. As an internal control to determine the transfection eciency, 0.03 mg pRL-TK plasmid (Clontech) was co-transfected. Whole cell extracts were prepared from the transfected cells after 30 or 48 h and then luciferase assays were performed using dual-luciferase reporter assay system (Promega) as described previously (Sato et al., 1998) .
Northern analysis
The human multiple tissue blots (Clontech) were hybridized with 53BP2 or p65 probes according to the manufacturer's recommendations. Human b-actin probe was used as a control.
Immuno¯uorescence staining
In order to examine colocalization of p65 and 53BP2, pEGFP-53BP2 was transfected into HeLa cells. Twenty-four hours after transfection, cells were immuno-stained with rabbit polyclonal antibody against p65 (Santa Cruz Biotechnology) as described previously (Sakurada et al., 1996) .
Cell death assay
Cells were cultured in 4-well chamber slides and transfected using SuperFect transfection reagent with a total of 1 mg of plasmid DNA as described above. The transfected cells were ®xed for 15 min in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst-33342 (Sigma) at room temperature for 15 min followed by washing in PBS. The apoptotic cells among the transfectants were identi®ed by their shrunken morphology and the condensed or fragmented nuclear morphology revealed by the Hoechst-33342 staining. Cell viability was evaluated by counting at least 500 transfected (GFP-positive) cells under¯uorescence microscope for each determination. Annexin V-PE analysis was performed by ®xing cells in 4% paraformaldehyde, washing with PBS, and incubating cells with Annexin V-PE (Pharmingen) in a binding buer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ) for 15 min at room temperature. After a ®nal wash in PBS, slides were dried and covered by coverslips with FluorSave reagent (Calibiochem, La Jolla, CA, USA). Microscopic examination was performed using¯uorescence microscopy (Olympus BX50, Tokyo, Japan) with ®lters WIB for GFP, WU for Hoechst-33342 staining and WIG for Annexin V-PE staining, respectively.
Western blot analysis
Whole-cell extracts were prepared from transfected HeLa cells. After electrophoresis on SDS ± PAGE, proteins were transferred to a PVDF (Millipore) membrane by semi-dry blotting. Filters were blocked overnight at 48C in PBS containing 0.05% Tween-20 and 5% non-fat dry milk and were incubated with mouse anti-GFP antibody (Clontech) (1 : 500 dilution). Filters were washed and then incubated with anti-mouse immunoglobulin antibody (1 : 2000 dilution) conjugated to horseradish peroxidase (Pierce, Rockford, IL, USA). Immunoblots were visualized as recommended by the manufacturer. The blot was stripped o the bound antibody and reprobed with anti-p65 antibody (Santa Cruz) 
